Glaucomatocyclitic crisis (GCC) was first reported by Posner and Schlossman in 1948 as unilateral ocular hypertension associated with mild anterior segment inflammation (uveitis), and few clinical symptoms. The exact etiology is not clear although there are several theories proposed, ranging from autoimmune to infectious. It is a self-limited condition with recurrent episodes, and during intervals between attacks the patient is asymptomatic. Treatment management is based on controlling the intraocular pressure and decreasing inflammation. Glaucomatocyclitic crisis (GCC), was described as a rare, recurrent and typically unilateral inflammatory ocular hypertensive disease.1 It generally affects one eye at a time, and its recurrence usually afflicts the same eye. Bilateral and simultaneous involvement is very uncommon. The individual attacks may last from a few hours to a few weeks, but rarely persist over two weeks. Episodes may occur with varying frequency and without any apparent cause. It can affect adults of all ages (reports range from 23 to 67 years), especially between the third and sixth decade of life
Alarifi, S., & Gebril, M. (2024). Glaucomatocyclitic Crisis review (review article). Zagazig University Medical Journal, 30(5), 1556-1562. doi: 10.21608/zumj.2024.295430.3432
MLA
Sarah Alarifi; Mariam Mohamed B. Gebril. "Glaucomatocyclitic Crisis review (review article)", Zagazig University Medical Journal, 30, 5, 2024, 1556-1562. doi: 10.21608/zumj.2024.295430.3432
HARVARD
Alarifi, S., Gebril, M. (2024). 'Glaucomatocyclitic Crisis review (review article)', Zagazig University Medical Journal, 30(5), pp. 1556-1562. doi: 10.21608/zumj.2024.295430.3432
VANCOUVER
Alarifi, S., Gebril, M. Glaucomatocyclitic Crisis review (review article). Zagazig University Medical Journal, 2024; 30(5): 1556-1562. doi: 10.21608/zumj.2024.295430.3432